Showing 2635 results
- https://www.novartis.com/news/novartis-completes-fda-filing-approval-millburn-facility-support-pluvicto-launch
- https://www.novartis.com/terms-use
- https://www.novartis.com/news/novartis-unwavering-support-one-year-from-start-war-ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
- https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosisNovartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
- https://www.novartis.com/news/media-releases/treatment-novartis-ultibro-breezhaler-improved-cardiac-function-copd-patients-lung-hyperinflationUltibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
- https://www.novartis.com/news/media-releases/novartis-new-data-show-cosentyx-improved-quality-life-over-5-years-two-thirds-patients-moderate-severe-plaque-psoriasisTwo thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/…
- https://www.novartis.com/news/media-releases/novartis-new-cosentyx-data-confirms-robust-efficacy-and-quality-life-improvements-scalp-psoriasisMajority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
- https://www.novartis.com/news/media-releases/novartis-forms-alliance-develop-medicines-treating-infectious-diarrheal-diseaseNovartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
- https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopa-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosisGlatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
- https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasisUS label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million…
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 264
- › Next page